William Blair Has Optimistic Outlook of TWST Q3 Earnings

Twist Bioscience Co. (NASDAQ:TWST) – Investment analysts at William Blair boosted their Q3 2025 earnings per share estimates for shares of Twist Bioscience in a research note issued on Monday, May 5th. William Blair analyst M. Larew now expects that the company will post earnings of ($0.52) per share for the quarter, up from their previous forecast of ($0.55). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.12) per share. William Blair also issued estimates for Twist Bioscience’s Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.14) EPS, Q1 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($1.34) EPS.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million.

Other equities research analysts also recently issued research reports about the stock. The Goldman Sachs Group lowered their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Tuesday. Guggenheim reissued a “buy” rating and set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday. Barclays lowered their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. JPMorgan Chase & Co. lowered their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a research note on Tuesday. Finally, Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $50.40.

Twist Bioscience Price Performance

NASDAQ TWST opened at $32.67 on Thursday. The company has a market cap of $1.95 billion, a P/E ratio of -9.66 and a beta of 2.54. Twist Bioscience has a 1 year low of $31.56 and a 1 year high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company has a fifty day simple moving average of $38.81 and a 200 day simple moving average of $43.74.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 918 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the sale, the senior vice president now directly owns 130,912 shares in the company, valued at approximately $5,355,609.92. This trade represents a 0.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 2,402 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $98,265.82. Following the sale, the chief executive officer now directly owns 662,692 shares in the company, valued at $27,110,729.72. The trade was a 0.36 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,991 shares of company stock worth $742,654. Insiders own 3.01% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently made changes to their positions in the stock. Barclays PLC grew its holdings in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after buying an additional 104,420 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Twist Bioscience during the 4th quarter worth about $1,059,000. Principal Financial Group Inc. increased its position in shares of Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after acquiring an additional 82,953 shares during the last quarter. Vanguard Group Inc. raised its holdings in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after acquiring an additional 189,791 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in Twist Bioscience by 34.5% in the fourth quarter. Wells Fargo & Company MN now owns 37,886 shares of the company’s stock valued at $1,761,000 after purchasing an additional 9,722 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.